Zusammenfassung
Gadolinium(Gd)-haltige Kontrastmittel (KM) werden seit 1988 in der klinischen MRT-Routinediagnostik weltweit eingesetzt. Dabei wurden alle in der Routine verwendeten Kontrastmittel in der zugelassenen Dosierung hinsichtlich Verträglichkeit, Nebenwirkungsprofil und diagnostischer Wirksamkeit lange Zeit als sicher eingestuft. Mit der Beobachtung der nephrogenen systemischen Fibrose (NSF) und der Gd-Retention im Gehirn änderte sich diese Ansicht jedoch und führte in Europa zum Entzug bzw. zur Einschränkung der Zulassung linearer Gd-Chelate. Insbesondere die NSF sowie die akute Unverträglichkeitsreaktion sind bei der Betrachtung Gd-haltiger Kontrastmittel von primärer klinischer Relevanz. Die schon seit Langem in der Literatur beschriebenen Ablagerungen von gadoliniumhaltigen Strukturen bzw. Strukturkomplexen im Körper wurden in den letzten Jahren insbesondere durch Veröffentlichungen von Ablagerungen im Gehirn sowie auch im Knochenmark wieder in den Vordergrund gerückt, jedoch wurde bisher keine klinische Beschwerdesymptomatik und keine nachhaltige Konsequenz für die Gesundheit der Patienten hierdurch beobachtet. Als Morbus Gadolinium wird ein von überwiegend online aktiven Patienten(interessens)gruppen gebildeter, wissenschaftlich nicht sicher belegter Symptomkomplex beschrieben, der sich nach Anwendung von gadoliniumhaltigen Kontrastmitteln mit großem Beschwerdespektrum offenbart. Die Betroffenen sind von teils chronisch persistierenden, teils remittierenden, und nicht durch andere (Vor‑)Erkrankungen zu erklärenden Beschwerden geplagt.
Abstract
Gadolinium (Gd)-based contrast agents have been routinely used worldwide in diagnostic MRI since 1988. All routinely applied contrast agents for clinical use were considered extremely safe with regard to tolerance, adverse effects and diagnostic efficacy and when used at Food and Drug Administration-approved doses. With the identification of Gd-associated disorders, namely nephrogenic systemic fibrosis and adverse reactions, and in the longer term Gd-retention in the brain, this view changed and led to the withdrawal or restriction of approval of linear Gd chelates in Europe. Even though Gd deposition in different human body areas was described very early, recently published literature of intracerebral accumulation of contrast agents as well as deposition in bone have created surprising attention. Not only was the fact of Gd deposition in the body well known for many years, but there is currently no clinical evidence of patient symptoms and no resulting health issues of patients have been observed yet. The expression “gadolinium deposition disease” has been termed by active patient advocacy groups with an online presence with reports of individual members stating a broad spectrum of disorders yielding a large symptom complex after administration of Gd-based contrast agents without evidence of any pre-existing or otherwise underlying disease process which could explain the mentioned disorder.
Literatur
Hao D, Ai T, Goerner F, Hu X, Runge VM, Tweedle M (2012) MRI contrast agents: basic chemistry and safety. J Magn Reson Imaging 36(5):1060–1071
Bleicher AG, Kanal E (2008) Assessment of adverse reaction rates to a newly approved MRI contrast agent: review of 23,553 administrations of gadobenate dimeglumine. Ajr Am J Roentgenol 191(6):W307–W311
Bleicher AG, Kanal E (2008) A serial dilution study of gadolinium-based MR imaging contrast agents. Ajnr Am J Neuroradiol 29(4):668–673
Kanal E, Tweedle MF (2015) Residual or retained gadolinium: practical implications for radiologists and our patients. Radiology 275(3):630–634
Grobner T (2006) Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21(4):1104–1108
Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS (2006) Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17(9):2359–2362
Hope TA, High WA, Leboit PE, Chaopathomkul B, Rogut VS, Herfkens RJ, Brasch RC (2009) Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron. Radiology 253(2):390–398
Wertman R, Altun E, Martin DR, Mitchell DG, Leyendecker JR, O’Malley RB, Parsons DJ, Fuller ER III, Semelka RC (2008) Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 248(3):799–806
Fretellier N, Idee JM, Guerret S, Hollenbeck C, Hartmann D, Gonzalez W, Robic C, Port M, Corot C (2011) Clinical, biological, and skin histopathologic effects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis. Invest Radiol 46(2):85–93
Abujudeh HH, Kaewlai R, Kagan A, Chibnik LB, Nazarian RM, High WA, Kay J (2009) Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. Radiology 253(1):81–89
Altun E, Martin DR, Wertman R, Lugo-Somolinos A, Fuller ER III, Semelka RC (2009) Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy—report from two U.S. universities. Radiology 253(3):689–696
Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D (2014) High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 270(3):834–841
Murata N, Gonzalez-Cuyar LF, Murata K, Fligner C, Dills R, Hippe D, Maravilla KR (2016) Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and Bone tissue: preliminary results from 9 patients with normal renal function. Invest Radiol 51(7):447–453
Kanda T, Fukusato T, Matsuda M, Toyoda K, Oba H, Kotoku J, Haruyama T, Kitajima K, Furui S (2015) Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 276(1):228–232
McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Murray DL, Thielen KR, Williamson EE, Eckel LJ (2015) Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 275(3):772–782
Joffe P, Thomsen HS, Meusel M (1998) Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 5(7):491–502
Gibby WA, Gibby KA, Gibby WA (2004) Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Invest Radiol 39(3):138–142
Darrah TH, Prutsman-Pfeiffer JJ, Poreda RJ, Ellen CM, Hauschka PV, Hannigan RE (2009) Incorporation of excess gadolinium into human bone from medical contrast agents. Metallomics 1(6):479–488
Runge VM (2000) Safety of approved MR contrast media for intravenous injection. J Magn Reson Imaging 12(2):205–213
Weiss KL (1990) Severe anaphylactoid reaction after i.v. Gd-DTPA. Magn Reson Imaging 8(6):817–818
Beaudouin E, Kanny G, Blanloeil Y, Guilloux L, Renaudin JM, Moneret-Vautrin DA (2003) Anaphylactic shock induced by gadoterate meglumine (DOTAREM). Eur Ann Allergy Clin Immunol 35(10):382–385
Runge VM (2001) Safety of magnetic resonance contrast media. Top Magn Reson Imaging 12(4):309–314
Ansell G, Tweedie MC, West CR, Evans P, Couch L (1980) The current status of reactions to intravenous contrast media. Invest Radiol 15(6 Suppl):32–39
Jung JW, Kang HR, Kim MH, Lee W, Min KU, Han MH, Cho SH (2012) Immediate hypersensitivity reaction to gadolinium-based MR contrast media. Radiology 264(2):414–422
Kanal E, Maravilla K, Rowley HA (2014) Gadolinium contrast agents for CNS imaging: current concepts and clinical evidence. Ajnr Am J Neuroradiol 35(12):2215–2226
Semelka RC, Ramalho M, AlObaidy M, Ramalho J (2016) Gadolinium in humans: a family of disorders. Ajr Am J Roentgenol 207(2):229–233
ESUR Contrast Media Safety Committee (2018) ESUR Contrast Media guidelines version 10.0
American College of Radiology (ACR), Committee on Drugs and Contrast Media (2017) ACR manual on contrast media. American College of Radiology, (version 10.3)
Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, Leboit PE (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356(9234):1000–1001
Broome DR (2008) Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 66(2):230–234
Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA (2007) Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Ajr Am J Roentgenol 188(2):586–592
Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, Djamali A (2007) Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243(1):148–157
Shabana WM, Cohan RH, Ellis JH, Hussain HK, Francis IR, Su LD, Mukherji SK, Swartz RD (2008) Nephrogenic systemic fibrosis: a report of 29 cases. Ajr Am J Roentgenol 190(3):736–741
Kallen AJ, Jhung MA, Cheng S, Hess T, Turabelidze G, Abramova L, Arduino M, Guarner J, Pollack B, Saab G, Patel PR (2008) Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. Am J Kidney Dis 51(6):966–975
Nandwana SB, Moreno CC, Osipow MT, Sekhar A, Cox KL (2015) Gadobenate Dimeglumine administration and Nephrogenic systemic fibrosis: is there a real risk in patients with impaired renal function? Radiology 276(3):741–747
Abraham JL, Thakral C, Skov L, Rossen K, Marckmann P (2008) Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 158(2):273–280
Collidge TA, Thomson PC, Mark PB, Traynor JP, Jardine AG, Morris ST, Simpson K, Roditi GH (2007) Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 245(1):168–175
Rosenkranz AR, Grobner T, Mayer GJ (2007) Conventional or Gadolinium containing contrast media: the choice between acute renal failure or Nephrogenic Systemic Fibrosis? Wien Klin Wochenschr 119(9–10):271–275
Sanyal S, Marckmann P, Scherer S, Abraham JL (2011) Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis—an autopsy-based review. Nephrol Dial Transplant 26(11):3616–3626
Christensen KN, Lee CU, Hanley MM, Leung N, Moyer TP, Pittelkow MR (2011) Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 64(1):91–96
Rocklage SM, Worah D, Kim SH (1991) Metal ion release from paramagnetic chelates: what is tolerable? Magn Reson Med 22(2):216–221
Tweedle MF (1992) Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. Invest Radiol 27(Suppl 1):2–6
Xia D, Davis RL, Crawford JA, Abraham JL (2010) Gadolinium released from MR contrast agents is deposited in brain tumors: in situ demonstration using scanning electron microscopy with energy dispersive X‑ray spectroscopy. Acta Radiol 51(10):1126–1136
Errante Y, Cirimele V, Mallio CA, Di L. V, Zobel BB, Quattrocchi CC (2014) Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol 49(10):685–690
Quattrocchi CC, Mallio CA, Errante Y, Beomonte ZB (2015) High T1 signal intensity in dentate nucleus after multiple injections of linear gadolinium chelates. Radiology 276(2):616–617
Quattrocchi CC, Mallio CA, Errante Y, Cirimele V, Carideo L, Ax A, Zobel BB (2015) Gadodiamide and dentate nucleus T1 Hyperintensity in patients with Meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Invest Radiol 50(7):470–472
Cao Y, Huang DQ, Shih G, Prince MR (2016) Signal change in the dentate nucleus on T1-weighted MR images after multiple administrations of Gadopentetate Dimeglumine versus Gadobutrol. Ajr Am J Roentgenol 206(2):414–419
Kanda T, Osawa M, Oba H, Toyoda K, Kotoku J, Haruyama T, Takeshita K, Furui S (2015) High signal intensity in dentate nucleus on Unenhanced T1-weighted MR images: association with linear versus Macrocyclic gadolinium chelate administration. Radiology 275(3):803–809
Weberling LD, Kieslich PJ, Kickingereder P, Wick W, Bendszus M, Schlemmer HP, Radbruch A (2015) Increased signal intensity in the dentate nucleus on Unenhanced T1-weighted images after Gadobenate Dimeglumine administration. Invest Radiol 50(11):743–748
Radbruch A, Weberling LD, Kieslich PJ, Hepp J, Kickingereder P, Wick W, Schlemmer HP, Bendszus M (2015) High-signal intensity in the dentate nucleus and Globus Pallidus on Unenhanced T1-weighted images: evaluation of the Macrocyclic gadolinium-based contrast agent Gadobutrol. Invest Radiol 50(12):805–810
Radbruch A, Weberling LD, Kieslich PJ, Hepp J, Kickingereder P, Wick W, Schlemmer HP, Bendszus M (2016) Intraindividual analysis of signal intensity changes in the dentate nucleus after consecutive serial applications of linear and Macrocyclic gadolinium-based contrast agents. Invest Radiol 51(11):683–690
Stojanov DA, Aracki-Trenkic A, Vojinovic S, Benedeto-Stojanov D, Ljubisavljevic S (2016) Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. Eur Radiol 26(3):807–815
Schneider GK, Stroeder J, Roditi G, Colosimo C, Armstrong P, Martucci M, Buecker A, Raczeck P (2017) T1 signal measurements in pediatric brain: findings after multiple exposures to Gadobenate Dimeglumine for imaging of Nonneurologic disease. Ajnr Am J Neuroradiol 38(9):1799–1806
Bjornerud A, Vatnehol SAS, Larsson C, Due-Tonnessen P, Hol PK, Groote IR (2017) Signal enhancement of the dentate nucleus at Unenhanced MR imaging after very high cumulative doses of the Macrocyclic gadolinium-based contrast agent Gadobutrol: an observational study. Radiology 285(2):434–444
Ramalho J, Castillo M, AlObaidy M, Nunes RH, Ramalho M, Dale BM, Semelka RC (2015) High signal intensity in Globus Pallidus and dentate nucleus on Unenhanced T1-weighted MR images: evaluation of two linear gadolinium-based contrast agents. Radiology 276(3):836–844
Dekkers IA, Roos R, van der Molen AJ (2018) Gadolinium retention after administration of contrast agents based on linear chelators and the recommendations of the European Medicines Agency. Eur Radiol 28(4):1579–1584
Prosch H, Grois N, Wnorowski M, Steiner M, Prayer D (2007) Long-term MR imaging course of neurodegenerative Langerhans cell histiocytosis. Ajnr Am J Neuroradiol 28(6):1022–1028
Maeda H, Sato M, Yoshikawa A, Kimura M, Sonomura T, Terada M, Kishi K (1997) Brain MR imaging in patients with hepatic cirrhosis: relationship between high intensity signal in basal ganglia on T1-weighted images and elemental concentrations in brain. Neuroradiology 39(8):546–550
Mochizuki H, Kamakura K, Masaki T, Okano M, Nagata N, Inui A, Fujisawa T, Kaji T (1997) Atypical MRI features of Wilson’s disease: high signal in globus pallidus on T1-weighted images. Neuroradiology 39(3):171–174
Frenzel T, Apte C, Jost G, Schockel L, Lohrke J, Pietsch H (2017) Quantification and assessment of the chemical form of residual gadolinium in the brain after repeated administration of gadolinium-based contrast agents: comparative study in rats. Invest Radiol 52(7):396–404
Murata N, Murata K, Gonzalez-Cuyar LF, Maravilla KR (2016) Gadolinium tissue deposition in brain and bone. Magn Reson Imaging 34(10):1359–1365
Maximova N, Gregori M, Zennaro F, Sonzogni A, Simeone R, Zanon D (2016) Hepatic gadolinium deposition and reversibility after contrast agent-enhanced MR imaging of pediatric Hematopoietic stem cell transplant recipients. Radiology 281(2):418–426
European Medicine Agency (2018) EMA’s final opinion confirms restrictions on use of linear gadolinium agents in body scans. https://www.ema.europa.eu (Erstellt: 23. Nov. 2017). Zugegriffen: 6. Dez. 2018 (EMA/625317/2017)
Taoka T, Naganawa S (2018) Gadolinium-based contrast media, cerebrospinal fluid and the Glymphatic system: possible mechanisms for the deposition of gadolinium in the brain. Magn Reson Med Sci 17(2):111–119
Welk B, McArthur E, Morrow SA, MacDonald P, Hayward J, Leung A, Lum A (2016) Association between gadolinium contrast exposure and the risk of parkinsonism. JAMA 316(1):96–98
Cocozza S, Pontillo G, Lanzillo R, Russo C, Petracca M, Di SM, Paolella C, Vola EA, Criscuolo C, Moccia M, Lamberti A, Monti S, Brescia MV, Elefante A, Palma G, Tedeschi E, Brunetti A (2019) MRI features suggestive of gadolinium retention do not correlate with expanded disability status scale worsening in multiple sclerosis. Neuroradiology 61(2):155–162
McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Paolini MA, Murray DL, Williamson EE, Eckel LJ (2017) Gadolinium deposition in human brain tissues after contrast-enhanced MR imaging in adult patients without Intracranial abnormalities. Radiology 285(2):546–554
McDonald RJ, McDonald JS, Dai D, Schroeder D, Jentoft ME, Murray DL, Kadirvel R, Eckel LJ, Kallmes DF (2017) Comparison of gadolinium concentrations within multiple rat organs after intravenous administration of linear versus Macrocyclic gadolinium chelates. Radiology 285(2):536–545
Forslin Y, Shams S, Hashim F, Aspelin P, Bergendal G, Martola J, Fredrikson S, Kristoffersen-Wiberg M, Granberg T (2017) Retention of gadolinium-based contrast agents in multiple sclerosis: retrospective analysis of an 18-year longitudinal study. Ajnr Am J Neuroradiol 38(7):1311–1316
Semelka RC, Ramalho J, Vakharia A, AlObaidy M, Burke LM, Jay M, Ramalho M (2016) Gadolinium deposition disease: Initial description of a disease that has been around for a while. Magn Reson Imaging 34(10):1383–1390
Gadolinium Toxicity (2018) The lighthouse project. www.gadoliniumtoxicity.com. Zugegriffen: 4. Dez. 2018
Gadolinium-Vergiftung.de (2018) Informationen und Netzwerk für Betroffene. https://www.gadolinium-vergiftung.de/gadolinium-vergiftung-mrt-kontrastmittel-symptome/. Zugegriffen: 4. Dez. 2018
Gathings RM, Reddy R, Santa CD, Brodell RT (2015) Gadolinium-associated plaques: a new, distinctive clinical entity. Jama Dermatol 151(3):316–319
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
P. Fries arbeitet wissenschaftlich an Forschungsprojekten mit der Firma Guerbet. A. Bücker ist wissenschaftlich für die Firmen Bracco und Guerbet tätig. G. Schneider arbeitet wissenschaftlich für die Firma Bracco und ist für Selbige Mitglied des Advisory Boards. Zusätzlich werden im Auftrag der Firma Bracco Vortragstätigkeiten wahrgenommen. P. Raczeck gibt an, dass es keinen Interessenskonflikt gibt.
Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Rights and permissions
About this article
Cite this article
Raczeck, P., Fries, P., Bücker, A. et al. Gadoliniumablagerungen – Morbus Gadolinium. Radiologe 59, 435–443 (2019). https://doi.org/10.1007/s00117-019-0522-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00117-019-0522-9
Schlüsselwörter
- Gadoliniumhaltige Kontrastmittel
- Nephrogene systemische Fibrose
- Akute Unverträglichkeitsreaktionen
- Neurologische Beschwerden
- Gadolinium-Chelate